KVUE

#414
Kenvue Inc.
17.3701 USD
+0.55%
Settore: Beni di Consumo Difensivi
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
17.3250
17.3850
Intervallo Annuale
14.0200
19.1750
Variazione giornaliera
+0.55%
Variazione Mensile
-1.31%
Variazione di 6 mesi
+15.19%
Variazione Annuale
+15.19%
Chiusura Precedente
17.2750
Apertura
17.3400
Bid
Ask
Minimo
17.3250
High
17.3850
Volume
366
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
  • Market Capitalization 33.2938 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
22.62
Rapporto prezzo/fatturato
2.19
Dividendi per azione
0.82
Rendimento da dividendi %
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

Notizie